News

Deal Announcements

Clementia Pharma Lands Series A VC Investment

Tuesday, January 6, 2015 5:47:00 AM PDT | VentureDeal
   Dorval, Canada  --  Clementia Pharmaceuticals has secured $10 million in its Series A venture capital financing round.

Clementia says that it is "dedicated to the development and commercialization of treatments for people living with rare diseases by exploiting the use of novel Retinoic acid receptor gamma agonists."

OrbiMed Advisors led the round, which also included BDC Venture Capital.

Clementia said that it would use the proceeds to support development of its lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive.

David Bonita from OrbiMed and Jean-François Pariseau from BDC were the venture firm partners involved in the transaction.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1